RCS - Creo Medical Group - Speedboat® UltraSlim roll-out reaches Asia Pacific

Creo MedicalAnnouncement

31/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe4008Ba&default-theme=true

RNS Number : 4008B  Creo Medical Group PLC  31 January 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

The controlled market release has seen the device used in the UK, USA, LATAM
and now APAC since launch in December 2023

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces continued progress on the
phased market release of its latest device, Speedboat® UltraSlim, which has
now been successfully used in the Asia Pacific region ("APAC") for the first
time.

 

Speedboat® UltraSlim was used at the Prince of Wales Hospital Hong Kong in
late January, where Dr. Hon Chi Yip and Dr. Simon Chu performed several
procedures to treat precancerous lesions in the colon and stomach.

 

Since December 2023 Speedboat® UltraSlim has been successfully used in
multiple clinical applications and in multiple jurisdictions: the UK, USA,
LATAM and now APAC, as well as expanding indications treating different
disease states and conditions. The device has been used to treat precancerous
lesions in the colon, oesophagus and stomach as well as during procedures to
surgically correct gastric and oesophageal abnormalities to help patients with
swallowing and acid reflux disorders. In all cases these procedures help move
patients from operating theatre procedures to endoscopic procedures with the
inherent reduced impact on the patient and associated costs.

 

Dr. Hon Chi Yip, Assistant Professor at the Division of Upper Gastrointestinal
and Metabolic Surgery, Department of Surgery, Faculty of Medicine, The Chinese
University of Hong Kong said: "The new Speedboat® UltraSlim allows for use
with a broader range of endoscopes, providing better access and handling. The
performance of the advanced energy has increased the efficiency of the
procedure."

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "We're very
pleased that Speedboat® UltraSlim has now reached the Asia Pacific region,
representing tremendous progress with the phased initial market release in a
short period of time. The team have done a terrific job with the regional
regulatory steps necessary to enable this limited market release programme and
we are excited to extend the roll-out to reach all of our customers in the
coming months. APAC represents the fourth continent where the device has now
been used in clinic and along with Dr. Hon Chi Yip and Dr. Simon Chu, we have
had fantastic feedback from all customers who have so far had access to the
new technology."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

About Creo Medical

 

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

About Speedboat® UltraSlim

 

Speedboat® UltraSlim is the third device in Creo's Speedboat® family of
products, and is targeting the therapeutic treatment of disease in the GI
tract (including cancer of the Bowel, Stomach and Oesophagus) as well as
surgical procedures to deal with abnormalities resulting in swallowing
disorders and, in some cases, gastric reflux. This latest generation Speedboat
has broad application in the GI tract due to a smaller configuration, ensuring
compatibility with a wide range of colonoscopes and gastroscopes.

 

Powered by Creo's CROMA advanced energy platform, Speedboat® UltraSlim
delivers fluid as well as advanced bipolar RF energy for controlled cutting
and high frequency MW energy for controlled coagulation of tissue in the GI
tract. The device is the culmination of a long programme of work to further
miniaturise Creo's technology, and is compatible with the working channel of
all commercially available endoscopes accessing the vast majority of GI
endoscopic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAWPUCCGUPCGPU